Another Covid-19 antibody drug has FDA approval. This one--the third--was developed by GlaxoSmithKline and Vir. Eligibility criteria for the drug have expanded, but CP3 Director Dr. Walid Gellad told The New York Times, “[P]eople aren’t getting them who could benefit from them, and having another one on the market doesn’t necessarily solve that."